Quarterly Report · 10-Q

Natera, Inc.

NTRANASDAQEQUITYCurrent

Quarterly Report

Filed Nov 5, 2026Accepted Nov 5, 2026, 4:49 PM ESTCIK 1604821Accession 0001628280-26-071145

Company context

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, San Carlos, California, and Boulder, Colorado. For more information, visit www.natera.com.

Current securities

NTRANASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

NATERA, INC. · 10-Q · Filed 2026-11-05

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: NTRA
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000162828026071145 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.